CSII - Cardiovascular Systems, Inc.
| Previous Close | 29.51 |
| Open | 29.32 |
| Bid | 0.00 x 100 |
| Ask | 0.00 x 100 |
| Day's Range | 28.25 - 29.83 |
| 52 Week Range | 20.58 - 40.00 |
| Volume | 154,430 |
| Avg. Volume | 254,412 |
| Market Cap | 991.069M |
| Beta (3Y Monthly) | 3.24 |
| PE Ratio (TTM) | 1,503.16 |
| EPS (TTM) | 0.02 |
| Earnings Date | Feb 5, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.75 |
- GlobeNewswire•12 days ago
Analysis: Positioning to Benefit within Cardiovascular, Ennis, Sparton, LightPath Technologies, Blue Apron, and HFF — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•26 days ago
First Patients in Europe Treated with Cardiovascular Systems, Inc. Peripheral Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Germany have been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The German cases represent the first commercial use of Peripheral OAS in Europe. Dr. Tobias Achenbach, head of the Radiology Department at the St. Vincenz Hospital, Köln, where the first patients in Germany were treated by his colleagues Dr. Reza Asady and Dr. Ingo Benz, said, “CSI’s minimally invasive orbital atherectomy technology allows physicians to gently modify calcified plaque and enables peripheral revascularization for patients with severely calcified arteries.
- Business Wire•last month
First Patient in Hong Kong Treated with Cardiovascular Systems, Inc. Coronary Orbital Atherectomy System
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Diamondback 360® Coronary Orbital Atherectomy System (OAS). This procedure marks the first international coronary procedure taking place as a result of the company’s distribution agreement with OrbusNeich®. Dr. Michael Kang-Yin Lee, MBBS, FACC, FRCP, Director of Cardiac Catheterization Laboratory at the Division of Cardiology, Department of Medicine, Queen Elizabeth Hospital, Hong Kong, said, “Orbital Atherectomy is simple to use.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CSII earnings conference call or presentation 30-Oct-18 8:45pm GMT
Q1 2019 Cardiovascular Systems Inc Earnings Call
- Zacks•last month
Cardiovascular Systems' (CSII) Q1 Loss Wider Than Expected
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q1.
- Zacks•last month
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and 0.55%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Cardiovascular Systems: Fiscal 1Q Earnings Snapshot
On a per-share basis, the St. Paul, Minnesota-based company said it had a loss of 9 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Business Wire•last month
Cardiovascular Systems, Inc. Reports Fiscal 2019 First-Quarter Financial Results
Conference Call Scheduled for Today, October 30, 2018, at 3:45 PM CT
- Zacks•2 months ago
Cardiovascular Systems (CSII) Q1 Earnings Preview: What's Shaping Up?
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind Continental Building Products, Hornbeck Offshore Services, Digi International, Triple-S Management, Collegium Pharmaceutical, and Cardiovascular — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Cardiovascular Systems, Inc. to Webcast Fiscal 2019 First-Quarter Earnings Conference Call Tuesday, October 30
Live Webcast at 3:45 p.m. CT
- Simply Wall St.•2 months ago
Who Are Cardiovascular Systems Inc’s (NASDAQ:CSII) Major Shareholders?
If you want to know who really controls Cardiovascular Systems Inc (NASDAQ:CSII), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
- Zacks•3 months ago
Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global
Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.
- Business Wire•3 months ago
Cardiovascular Systems, Inc. Announces First Commercial Launch of Peripheral Orbital Atherectomy System Outside the United States
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The Hong Kong case is the first commercial use of Peripheral OAS outside of the United States.
- Zacks•3 months ago
Cardiovascular Systems Portfolio Strong, Competition Rife
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
- Zacks•3 months ago
Zacks.com featured highlights include: Cardiovascular, AMC, Osisko and Agnico Eagle
Zacks.com featured highlights include: Cardiovascular, AMC, Osisko and Agnico Eagle
- Zacks•3 months ago
Why Is Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report?
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GuruFocus.com•4 months ago
Cardiovascular Systems Inc (CSII) Files 10-K for the Fiscal Year Ended on June 30, 2018
Cardiovascular Systems Inc is a medical technology company developing solutions for vascular and coronary disease. Warning! GuruFocus has detected 4 Warning Sign with CSII. For the last quarter Cardiovascular Systems Inc reported a revenue of $59.2 million, compared with the revenue of $52.92 million during the same period a year ago.
- Zacks•4 months ago
Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
- Business Wire•4 months ago
Cardiovascular Systems Presents Liberty 360° Two-Year Outcomes at 2018 Amputation Prevention Symposium
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago. The LIBERTY 360° study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in patients with peripheral artery disease (PAD).
- Zacks•4 months ago
Cardiovascular Systems (CSII) Beats on Q4 Earnings & Revenues
Cardiovascular Systems (CSII) sees strength in Coronary device and peripheral device segments in Q4.
- Business Wire•4 months ago
Cardiovascular Systems, Inc. and Aerolase Corp. Sign Collaborative Agreement for Laser Atherectomy Technology
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has signed an agreement with Aerolase Corp. (Aerolase®) to co-develop a new laser atherectomy device for physicians to use in more effectively treating multiple forms of arterial disease. Scott Ward, CSI’s Chairman, President and Chief Executive Officer, said, “We believe there is an opportunity to leverage Aerolase’s innovative proprietary laser technology, which is FDA-cleared for dermatology and medical aesthetic uses, and supported by leading physicians in those fields.
- Zacks•4 months ago
Cardiovascular Systems (CSII) Q4 Earnings and Revenues Top Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 83.33% and 1.24%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
